AI Article Synopsis

  • The study aimed to assess how the FilmArray Pneumonia Panel (FAPP) affects the treatment of patients with ventilated hospital-acquired pneumonia (VHAP) by potentially guiding antimicrobial therapy.
  • Researchers tested respiratory fluids from 100 patients and compared FAPP results with traditional culture methods, while ensuring clinicians were not aware of these results during the study.
  • Findings indicated that using FAPP could significantly reduce the duration of broad-spectrum antibiotic use without raising the risk of treatment failure, suggesting it may be a beneficial tool for managing VHAP.

Article Abstract

Objectives: To investigate the potential impact of the syndromic multiplex FilmArray Pneumonia Panel (FAPP) on the antimicrobial treatment guidance of patients with ventilated hospital-acquired pneumonia (VHAP).

Methods: Respiratory fluids from 100 adult patients with VHAP, receiving invasive mechanical ventilation in three intensive care units from one French university hospital, were tested prospectively using FAPP. Conventional cultures were performed in parallel as routine practice. Clinicians were left blinded to the FAPP results. Antimicrobial therapies based on FAPP results were simulated by independent blinded experts according to a predefined algorithm and compared to 1) those prescribed in practice according to local guidelines (real-life), and 2) those that complied with the international ERS/ESICM/ESCMID/ALAT recommendations. The primary endpoint was the number of days of broad-spectrum antimicrobial therapy. Secondary endpoints were the rates of microbiological treatment failure and cost-effectiveness ratio.

Results: The predicted median duration of broad-spectrum antibiotics was 0 [0-1.25] day in the FAPP-based simulation, versus 2 [0-6] days in real-life (p<0.0001) and 2 [2-3.25] days in the recommendations-based simulation (p<0.0001). Treatment failure was predicted in 3% of cases with FAPP results versus observed in 11% in real-life (p=0.08) and 6% with recommendations-based simulation (p=0.37). The incremental cost-effectiveness ratio was 1 121 € [-7021; 6794] to avoid one day of non-optimized antimicrobial therapy.

Conclusions: Our results suggest that using FAPP in patients with VHAP has the potential to reduce the use of broad-spectrum antimicrobial therapy without increasing the risk of microbial treatment failure.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043525PMC
http://dx.doi.org/10.3389/fcimb.2022.804611DOI Listing

Publication Analysis

Top Keywords

potential impact
8
antimicrobial therapy
8
ventilated hospital-acquired
8
hospital-acquired pneumonia
8
fapp antimicrobial
8
impact rapid
4
rapid multiplex
4
multiplex pcr
4
antimicrobial
4
pcr antimicrobial
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!